Log in to save to my catalogue

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD durin...

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD durin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2696865281

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

About this item

Full title

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Publisher

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

Journal title

Gut, 2023-02, Vol.72 (2), p.295-305

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

More information

Scope and Contents

Contents

ObjectiveAntitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 antibody responses and protective immunity in infliximab-treated patients with IBD.DesignThird dose vaccine induced anti-SARS...

Alternative Titles

Full title

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2696865281

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2696865281

Other Identifiers

ISSN

0017-5749,1468-3288

E-ISSN

1468-3288

DOI

10.1136/gutjnl-2022-327570

How to access this item